Bacterial resistance to antibiotics is a major therapeutic problem.
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Indole-3-carbinol (I3C), used in this research, is a compound found in high concentrations in Brassica vegetables. It is produced from naturally occurring glucosinolates contained in a wide variety of plants. 7) I3C has recently become available as a nutritional supplement. Several studies have investigated its safety. Early studies have been promising, and will likely be followed up with large clinical trials. 8) In our previous study, I3C exhibited broad spectrum antimicrobial activities. Particularly, it showed a more potent antibacterial activity against Gram-positive bacteria than Gram-negative bacteria. The likely targets of I3C are the cytoplasmic membrane and DNA. 9, 10) The aim of the present study was to compare the activities of I3C against Gram-positive bacteria versus those against Gram-negative bacteria and to learn whether the outer membrane and/or MDR pumps were responsible for resistance to I3C. Additionally, we will discuss its synergistic activity with conventional antibiotics towards multi-drug resistant bacteria which were isolated clinically.
MATERIALS AND METHODS
Materials I3C and all antibiotics used in this study, were purchased from the Sigma Chemical Co. (St. Louis, Mo, U.S.A.). Stock solutions of I3C were prepared in dimethyl sulfoxide (DMSO) and stored at Ϫ20°C (Fig. 1) 11) After 24 h of incubation at 37°C, the minimal compound concentration that prevented the growth of a given test organism was determined and was defined as the MIC. Growth was assayed with a microtiter ELISA reader (Molecular Devices Emax, California, U.S.A.), by monitoring absorption at 620 nm.
Kinetics of the Killing of Bacteria The kinetics of the antibacterial action of I3C were evaluated with MRSA 1. Log-phase bacterial cells (2ϫ10 6 /ml) were incubated with I3C (64 mM, at two times the MIC) or propionic acid (540 mM, at two times the MIC), which was used as a positive control. Cells were obtained and spread on a MH agar plate, and then the colony forming units (CFUs) were counted after incubation for 24 h at 37°C.
12) The values represented the average of measurements conducted in triplicate of three independent assays.
MDR Pumps Inhibitor and Permeability Assay
The permeability of I3C on cell membranes, in the presence of ethylenediaminetetraacetic acid (EDTA) or 1,3-dicyclohexylcarbodiimide (DCCD), was also determined by an antibacterial susceptibility assay. To increase the permeability of the outer membrane, the activities were investigated in the presence or absence of EDTA. Thus, log-phase bacterial cells (2ϫ10 6 /ml) were incubated with I3C (at one-fourth the MIC) in the presence or absence of 0.05 mM EDTA. The culture was obtained and spread on an MH agar plate, and the CFUs were then counted after incubation for 24 h at 37°C. DCCD were used as a metabolic inhibitor of the F 0 F 1 ATPase to inhibit the MDR pumps.
13) The antibacterial susceptibility of I3C (at one-fourth the MIC), in the presence or absence of 20 mM DCCD, was also carried out under the same conditions. The results represent the average of measurements taken in triplicate from three independent assays.
Combination Effect of I3C with Conventional Antibiotics The combination effects of conventional antibiotics and I3C were determined by a checkerboard assay and the effects were evaluated using the fractional inhibitory concentration index (FICI). FICI was calculated using the following formula: FICIϭ(MIC Drug A in combination/MIC Drug A alone)ϩ (MIC Drug B in combination/MIC Drug B alone). In brief, the bacterial cells (2ϫ10 6 /ml) were inoculated into a MH broth and dispensed at 0.1 ml/well in 96-well microtiter plates. MICs were determined by a serial two-fold dilution of I3C and/or antibiotics. After 24 h of incubation at 37°C, the minimal compound concentration that prevented the growth of a given test organism was determined and was defined as the MIC.
The MIC values were determined by three independent assays and the FICI was calculated from both the FICI of I3C and antibiotics.
14) The FIC indexes Ͻ0.5, 0.5ՅFICIՅ0.75, 0.76ՅFICIՅ1, 1ϽFICIՅ4, and Ͼ4 were defined as synergy, partial synergy, additive effect, indifference, and antagonism, respectively. 15) 
RESULTS
In Vitro Antibacterial Activity The antibacterial activities of I3C and conventional antibiotics were investigated on human pathogenic bacteria, including the clinical isolates of multi-drug resistant bacteria, using the CLSI method, 11) and were described as the MIC. In the current study, ampicillin (Ap), chloramphenicol (Cm) and kanamycin (Km) were used as a positive control toward bacteria; Ap is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis, and Cm and Km inhibit protein synthesis. 16, 17) I3C presented a moderate activity against the Gram-positive bacteria MRSA with MIC values of 34-68 mM, a weak activity on the Gram-positive VSE and VRE with MIC values of 68-136 mM. MRSA strains were resistant to Km, but sensitive to Ap and Cm, respectively. VSE or VRE strains were resistant to Ap and Km, respectively, but sensitive to Cm. In a separate study, I3C was very weakly active or inactive against Gram-negative bacteria strains including the clinical isolates of MDREC and MDRPA with MIC values of 136-544 mM. MDREC and MDRPA strains were resistant to all conventional antibiotics tested (Table 1) . These results indicate that Gram-positive bacterial isolates are more susceptible to I3C than Gramnegative bacterial isolates.
To assess the killing potency of I3C, a killing-curve assay against MRSA 1 was conducted, and the results showed that I3C has antibacterial activity through bactericidal effect. MRSA was significantly decreased at two times the MIC values of I3C in a time-dependent manner, similar to the de- crease observed in the presence of propionic acid (Fig. 2) . MDR Pumps Inhibitor and Permeability Assay Some reports have suggested that the difference of susceptibility between Gram-positive bacteria and Gram-negative bacteria has been caused by a permeability barrier, such as an outer membrane or MDR pumps. 18) In order to identify whether MDR pumps were responsible for resistance to I3C against Gram-negative bacteria, we investigated bacterial viability in the presence of I3C with DCCD; which can inhibit MDR pumps by ATP depletion. 13) The results showed that I3C in combination with DCCD significantly decreased the cell viability of MDREC 2 and MDRPA 2, whereas all other strains maintained their viability in the presence of I3C with 20 mM DCCD (data not shown).
Another component of the permeability barrier in Gramnegative bacteria is the outer membrane. The outer membrane including lipopolysaccharide (LPS) is a fairly effective barrier for amphipathic compounds. 19) In order to identify the effects of enhanced membrane permeability using EDTA, we examined the antibacterial activity of I3C under increased membrane permeability using 0.05 mM EDTA. EDTA is membrane-permeabilizing agent which can increase the permeability of the outer membrane in Gram-negative bacteria by binding LPS. 20) The results showed that I3C in combination with EDTA significantly decreased the cell viability of all Gram-negative bacteria tested, except MDREC 2 and MDRPA 2 strains ( Table 2 ).
The Combination Effect of I3C with Conventional Antibiotics
To estimate the general effect regarding the combination of I3C and conventional antibiotics, such as Ap, Cm, and Km, on antibacterial activity against the clinical isolates of multi-drug resistant bacteria, the FICI was determined by a checkerboard study. 14) When tested alone, I3C and other antibiotics showed weak antibacterial activity (Table 1) , however, the combination of Ap with I3C significantly improved antibacterial activity (Table 3) . Based on FICI calculations, the combination of I3C and Ap had a synergy or partial synergy against most strains tested, showed on FICI of 0.38-0.75 (Table 3) , whereas the combination of Cm or Km with I3C had only indifference, showed on FICI of 1-4 (data not shown). The FICI (Table 3) was calculated as described in Materials and Methods. DISCUSSION I3C has a moderate or weak antibacterial activity against the multi-drug resistant strains tested and that Gram-positive bacterial isolates are more susceptible to I3C than Gram-negative bacterial isolates (Table 1) . Antibiotics show antimicrobial effects by cidal or static action. I3C exhibited effect similar to propionic acid, which has been shown to be a cidal agent toward bacteria; the antibacterial activity of I3C is due to the killing action, as evidenced by killing-curve assay with MRSA (Fig. 2) .
In order to elucidate this disparity of antibacterial activity between Gram-positive and Gram-negative bacteria, the effects of the LPS-binding agent and the MDR pump inhibitor in antibacterial activity of I3C were investigated. There are few mechanisms that can resist antibiotic and toxic molecules in bacteria, and active efflux systems, which are responsible for resistance to a variety of structurally unrelated antibiotics and toxic compounds, and are being recognized more frequently in an increasing numbers of environmental Bacterial cells (2ϫ10 6 /ml) were incubated with I3C (at one-fourth the MIC) in the presence or absence of 0.05 mM EDTA. The viability was determined by using colony forming units (CFUs) and expressed as the percent of survivals. Control indicates no compound treatment. and clinical isolates. 21) However, antibacterial activity of I3C increases in the presence of the MDR pump inhibitor in only two strains tested (data not shown). The results demonstrated that MDR pumps are not major factor for resistance to I3C against the Gram-negative bacteria tested. However, experiments used by EDTA showed that the activity of I3C increase in the presence of the membrane-permeabilizing agent (Table  2 ). These results demonstrate that the antibacterial activity of I3C was affected by barrier action of LPS in the outer membrane rather than by MDRs against the Gram-negative bacteria tested.
We examined combinations of I3C and other conventional antibiotics with regard to multi-drug resistant bacteria. Combination antibiotic therapy has been used mainly to broaden the antibacterial spectrum and to prevent the development of resistance. The combination of I3C and Ap had a synergy or partial synergy effect against most strains tested (Table 3) . Ap has good bactericidal activity; however, it can be degraded by b-lactamase which is produced by various bacteria, including MRSA. It inhibits the synthesis of cell wall by acting as a competitive inhibitor of the enzyme transpeptidase and leads to autolysis in bacteria. 22) Also, the likely targets of I3C are the cytoplasmic membrane and DNA. 9, 10) If the entry of I3C into the cytoplasm or the cytoplasmic membrane is increased by changes in the permeability of the cell wall, the antibacterial activity of I3C, against multi-drug resistant bacteria, could be increased. In other words, when Ap inhibits the synthesis of cell wall, this raises the permeability of the cell wall to I3C. The mechanism by which such combination achieves synergy is believed to facilitate the entry of I3C into cells, after the partial disruption of the cell wall, through the action of Ap.
